1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Pharma Exhales, Dodges Financial Blow With Tariff Exemption

 
• By Jessica Merrill

Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.

Tariffs still could be added to pharmaceuticals later, analysts cautioned. (Shutterstock)
Key Takeaways
  • Pharmaceuticals are not subject to President Trump’s sweeping tariffs on most goods imported into the US, a reprieve for industry.
  • The situation remains fluid and tariffs still could be added to pharmaceuticals at a later date, some analysts cautioned.
  • Macroeconomic uncertainty caused by tariffs across sectors is expected to be an overhang on the high-risk area of drug development.

President Donald Trump’s remarks were not immediately clear, but it appears pharmaceuticals are exempt from a sweeping US tariff plan that targets almost all other goods and most American trading...

The executive order that Trump outlined on 2 April exempted a few products from the tariffs, including “copper, pharmaceuticals, semiconductors, lumber articles, certain critical minerals, and energy products.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By David Ridley

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By David Ridley

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By David Ridley

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.

More from HBW Insight

OTC Marketing Awards 2025 Open For Entries

 
• By Tom Gallen

Find out how to enter the OTC Marketing Awards before the 1 September entry deadline.

Haleon Study: Boosting Health Literacy Could Save Major Economies Over $300bn Per Year

 
• By David Ridley

By addressing disparities in health literacy, particularly in the areas of oral care, bone health, nutrition and air pollution, the consumer health industry can “save lives and billions in healthcare costs, boosting productivity and increasing GDP,” says a new report from Haleon and Economist Impact.

J&J Plots Next Steps Following Third Failure To Resolve Talc Cases Through Bankruptcy

 
• By Lauren Nardella

After a Texas judge denied a bankruptcy plan, Johnson & Johnson attorneys plan to focus on debunking what they see as dubious scientific claims in civil court.